These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 38928174)

  • 1. Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.
    Poniewierska-Baran A; Sobolak K; Niedźwiedzka-Rystwej P; Plewa P; Pawlik A
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.
    Li G; Liu X; Gu C; Ma G; Li S; Ma Z; Xiong Y; Jiang Y; Huang Q; Wu J; Wu Z; Liao W; Wu Q; Shi M
    J Transl Med; 2024 Aug; 22(1):718. PubMed ID: 39097734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
    Li F; Chen Y; Pang M; Yang P; Jing H
    Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects.
    Banday AH; Abdalla M
    Curr Med Chem; 2023; 30(28):3215-3237. PubMed ID: 35986535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.
    Yan SY; Fan JG
    World J Gastroenterol; 2024 Jun; 30(21):2734-2739. PubMed ID: 38899328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
    Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
    Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
    Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
    Zhang Q; Yang C; Gao X; Dong J; Zhong C
    Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.